Article
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Leukemia - 1 Jun 2008
Hochhaus A, Baccarani M, Deininger M, Apperley J F, Lipton J H, Goldberg S L, Corm S, Shah N P, Cervantes F, Silver R T, Niederwieser D, Stone R M, Dombret H, Larson R A, Roy L, Hughes T, Müller M C, Ezzeddine R, Countouriotis A M, Kantarjian H M
Abstract excerpt
Dasatinib, a potent inhibitor of BCR-ABL in vitro, is effective for patients with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. To provide a more definitive assessment of dasatinib in chronic-phase (CP)-CML, we report extended follow-up of a phase II trial, presenting data for the entire patient cohort (N=387). Dasatinib (70 mg) twice daily was administered to patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.